354 related articles for article (PubMed ID: 35015186)
1. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Cardiovasc Drugs Ther; 2023 Aug; 37(4):683-694. PubMed ID: 35015186
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
Ademi Z; Ofori-Asenso R; Zomer E; Owen A; Liew D
Eur J Prev Cardiol; 2021 Jul; 28(8):897-904. PubMed ID: 34298556
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
6. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults.
Xiang Y; Gan L; Du H; Hao Q; Aertgeerts B; Li S; Hu M
Int J Technol Assess Health Care; 2023 Aug; 39(1):e53. PubMed ID: 37650314
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia - An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS).
Kodera S; Morita H; Kiyosue A; Ando J; Komuro I
Circ J; 2018 Mar; 82(4):1076-1082. PubMed ID: 29367520
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
[TBL] [Abstract][Full Text] [Related]
10. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan.
Kodera S; Morita H; Kiyosue A; Ando J; Takura T; Komuro I
Circ J; 2018 Sep; 82(10):2602-2608. PubMed ID: 30033948
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
Gao L; Moodie M; Li SC
Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Kazi DS; Penko J; Coxson PG; Guzman D; Wei PC; Bibbins-Domingo K
Ann Intern Med; 2019 Feb; 170(4):221-229. PubMed ID: 30597485
[TBL] [Abstract][Full Text] [Related]
14. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Korman M; Wisløff T
Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis.
Yang H; Li N; Zhou Y; Xiao Z; Tian H; Hu M; Li S
Drug Des Devel Ther; 2020; 14():157-165. PubMed ID: 32021100
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
Abushanab D; Al-Badriyeh D; Marquina C; Bailey C; Jaam M; Liew D; Ademi Z
Curr Probl Cardiol; 2023 Aug; 48(8):101211. PubMed ID: 35460688
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
Davies GM; Vyas A; Baxter CA
J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
[TBL] [Abstract][Full Text] [Related]
20. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification.
Marquina C; Morton J; Zomer E; Talic S; Lybrand S; Thomson D; Liew D; Ademi Z
Value Health; 2023 Apr; 26(4):498-507. PubMed ID: 36442832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]